DOCSLIB.ORG

Simpler Alternative May Work in Place of Mohs

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Simpler Alternative May Work in Place of Mohs 28 Dermatologic Surgery S KIN & ALLERGY N EWS • October 2005 Simpler Alternative May Work in Place of Mohs BY JEFF EVANS Weatherhead said in an interview. about 3-4 mm. The specimen obtained tologist chooses a method to close the Senior Writer At the dermatology clinic at the Ottawa from that excision is then sent for patho- wound depending on the location and Hospital, Dr. Weatherhead has not had logic analysis of the margin. The derma- size of the defect. ■ Q UEBEC C ITY — A quasi-Mohs mi- positive margins in any patient who has crographic surgery procedure involving undergone the procedure. excision and curettage with pathologic “In my hands it’s been a very good tool, analysis of margins may be a practical way but there’s always risk, when you do any of treating skin cancer patients in areas surgical procedure, that you might have a that do not have access to Mohs surgeons, margin that’s still involved,” he said, “in Louis Weatherhead, M.B., said at the an- which case, then, many times in [basal cell nual conference of the Canadian Derma- carcinomas] you have to determine the tology Association. amount of involvement and whether or “In many areas in Canada, we do not not you’re going to go back and do have access to Mohs surgery,” said Dr. surgery or just observe, because in many Weatherhead, director of surgical derma- instances the healing gets rid of residual tology at the University of Ottawa. tumor.” “Many plastic surgeons in the Ottawa re- The first step of the procedure is “like gion will not deal with a skin malignancy,” doing your first Mohs cut,” Dr. Weather- Skin cancer patient undergoing a quasi-Mohs procedure. From left to right: malignant he said. head said, because it involves tangentially lesion is excised; curettage ensures clear margins; a rotational flap closes wound. The alternative to Mohs surgery, which excising the lesion and submitting the Dr. Weatherhead teaches to his residents in specimen for pathologic—but not imme- Ottawa, is easy to learn and provides “clin- diate—analysis. But the similarity between ically good results in clearance of tumor as the procedure and Mohs stops there, be- well as postoperative appearance,” he said. cause “we don’t have the facility to con- The “poor man’s Mohs procedure” has tinue it.” had a recurrence rate of about 2%-4% Curettage is performed to remove any residual tumor up to normal tissue and to EATHERHEAD over a 5-year period, he said. The relatively W simple technique involves simple shaving delineate the borders of the tumor. Fol- and curettage plus excision, which most lowing hemostasis of the wound, Dr. OUIS . L R HOTOS COURTESY dermatologists know how to do, Dr. Weatherhead excises a surgical margin of P D Final cosmetic result seen 1 year after having a quasi-Mohs Salex™ (6% Salicylic Acid) Lotion Rotational flap is sutured in place (left). Good healing micrographic surgery Rx Only of the wound is seen after 1 week (right). procedure. FOR TOPICAL USE ONLY. NOT FOR OPHTHALMIC, ORAL OR INTRAVAGINAL USE. INDICATIONS AND USAGE II. Drugs changing salicylate levels by altering Carcinogenesis, Mutagenesis, renal tubular reabsorption: Impairment of Fertility: No data are For Dermatologic Use: Salex™ Lotion is a topical available concerning potential carcinogenic or aid in the removal of excessive keratin in hyperker- DRUG DESCRIPTION OF INTERACTION reproductive effects of Salex™ Lotion. It has been atotic skin disorders, including verrucae, and the Radio Frequency Plus Vacuum shown to lack mutagenic potential in the Ames various ichthyoses (vulgaris, sex-linked and lamel- Corticosteroids Decreases plasma salicylate Salmonella test. lar), keratosis palmaris and plantaris, keratosis level; tapering doses of pilaris, pityriasis rubra pilaris, and psoriasis steroids may promote ADVERSE REACTIONS (including body, scalp, palms and soles). salicylism. Excessive erythema and scaling conceivably could May Lessen Wrinkle Tx Pain Acidifying Agents Increases plasma salicylate For Podiatric Use: Salex™ Lotion is a topical aid in result from use on open skin lesions. the removal of excessive keratin on dorsal and level. plantar hyperkeratotic lesions. Topical prepara- Alkanizing Agents Decreased plasma salicylate OVERDOSAGE tions of 6% salicylic acid have been reported to be levels. See Warnings. BY PATRICE WENDLING “I think because we’re taking up the useful adjunctive therapy for verrucae plantares. III. Drugs with complicated interactions with CONTRAINDICATIONS salicylates: DOSAGE AND ADMINISTRATION Chicago Bureau skin and compressing the nerves or the cir- Salex™ Lotion should not be used in any patient DRUG DESCRIPTION OF The preferable method of use is to apply Salex™ INTERACTION culation affecting those nerves, we’re do- known to be sensitive to salicylic acid or any other Lotion thoroughly to the affected area and occlude listed ingredients. Salex™ Lotion should not be Heparin Salicylate decreases platelet the area at night. Preferably, the skin should be PARIS — A new device that uses vacu- ing something. We’re just not sure what, used in children under 2 years of age. adhesiveness and interferes hydrated for at least five minutes prior to applica- with hemostasis in heparin- tion. The medication is washed off in the morning um suction in combination with radio fre- but it is effective and doesn’t hurt,” Dr. WARNINGS treated patients. and if excessive drying and/or irritation is observed a bland cream or lotion may be applied. quency painlessly treats facial lines and Gold said in an interview. Prolonged use over large areas, especially in chil- Pyrazinamide Inhibits pyrazinamide- Once clearing is apparent, the occasional use of dren and those patients with significant renal or induced hyperuricemia. Salex™ Lotion will usually maintain the remission. wrinkles, Michael H. Gold, M.D., report- In a study of 46 patients aged 30-65 hepatic impairment, could result in salicylism. Uricosuric Agents Effect of probenemide, In those areas where occlusion is difficult or Concomitant use of other drugs which may con- ed at the Fourth International Academy of years with periorbital and nasal labial wrin- sulfinpyrazone and impossible, application may be made more fre- tribute to elevated serum salicylate levels should phenylbutazone inhibited. quently; hydration by wet packs or baths prior to be avoided where the potential for toxicity is pres- Cosmetic Dermatology World Congress. kles, 1%-2% of patients reported pain The following alterations of laboratory tests have been report- application apparently enhances the effect. Unless ent. In children under 12 years of age and those ed during salicylate therapy: hands are being treated, hands should be rinsed Radio frequency (RF) devices have been with the first two treatments. Patients re- patients with renal or hepatic impairment, the area thoroughly after application. to be treated should be limited and the patient LABORATORY TESTS EFFECT OF SALICYLATES used successfully over the last 5 years to ported pain of 0 or 1 on a 4-point scale, monitored closely for signs of salicylate toxicity: Thyroid Function Decreased PBI; increased HOW SUPPLIED nausea, vomiting, dizziness, loss of hearing, tinni- improve skin texture and laxity, but their with 0 being no pain and 4 being in- T3 uptake. tus, lethargy, hyperpnea, diarrhea, and psychic Salex™ Lotion is available in 14 fl oz (414 ml) disturbances. In the event of salicylic acid toxicity, Urinary Sugar False negative with glucose (NDC 0064-4011-14) bottles. use has been limited because patients com- tractable pain, he said. Seven patients were oxidase; false positive with the use of Salex™ Lotion should be discontinued. Store at controlled room temperature Clinitest with high-dose plain the treatments are too painful, said lost to follow-up. No one dropped out of Fluids should be administered to promote urinary salicylate therapy (2-5g q.d.). 20° - 25°C (68° - 77°F). Do not freeze. excretion. Treatment with sodium bicarbonate Dr. Gold of Nashville, Tenn. the study because of pain or an adverse (oral or intravenous) should be instituted as 5-Hydroxyindole False negative with appropriate. acetic acid fluorometric test. Efforts have been made with varying de- event, said Dr. Gold. All of the 39 patients Due to potential risk of developing Reye’s syn- Acetone, ketone False positive FeCl3 in grees of success to reduce the pain by who completed the study had at least a 50% drome, salicylate products should not be used in bodies Gerhardt reaction; red color persists with boiling. children and teenagers with varicella or influenza, changing machine parameters, using mul- improvement in wrinkling based on evalu- unless directed by a physician. 17-OH corticosteroids False reduced values with > 4.8g q.d. salicylate. tiple passes at lower power, or by incorpo- ation by blinded clinicians. Patients were PRECAUTIONS Vanilmandelic acid False reduced values. For external use only. Avoid contact with eyes and rating RF with intense pulsed light devices. able to maintain the improvements 6 Uric acid May increase or decrease other mucous membranes. depending on dose. General anesthesia or intravenous medica- months posttreatment. DRUG INTERACTIONS Prothrombin Decreased levels; slightly Marketed by: tions have been used, but few patients have The maximum benefit is seen after the The following interactions are from a published increased prothrombin time. Coria Laboratories, Ltd. Fort Worth, TX 76107 been willing to incur the associated risks. fifth or sixth treatment. The optimal num- review and include reports concerning both oral Pregnancy (Category C): Salicylic acid 1-800-441-8227 and topical salicylate administration. The relation- has been shown to be teratogenic in rats and mon- The new bipolar RF device, Aluma Skin ber and best interval between treatments ship of these interactions to the use of Salex™ keys. It is difficult to extrapolate from oral doses of Manufactured by: Lotion is not known. acetylsalicylic acid used in these studies to topical DPT Laboratories, Ltd.
Load more

Recommended publications
  • Sulfinpyrazone 100Mg and 200Mg Tablets (Sulfinpyrazone)
    Prescribing information sulfinpyrazone 100mg and 200mg tablets (sulfinpyrazone) Presentation: Coated tablets agents, sulphonamides, penicillin, theophylline, phenytoin, non- indication: Chronic, including tophaceous gout; recurrent gouty steroidal antirheumatic drugs. arthritis; hyperuricaemia Pregnancy and lactation: Used with caution in pregnant women, Dosage and administration: Route of administration: Oral. Adults: weighing the potential risk against the possible benefits. It is not known 100-200mg daily increasing gradually (over the first two or three whether the active substance or its metabolite(s) pass into breast milk. weeks) to 600mg daily (rarely 800mg), and maintained until the For safety reasons mothers should refrain from taking the drug. serum urate level has fallen within the normal range. Maintenance Undesirable effects: Mild transient gastro-intestinal upsets, such dose may be as low as 200mg daily. Children: Paediatric usage as nausea, vomiting, diarrhea, gastro-intestinal bleeding and not established. ulcers, acute renal failure, salt and water retention, allergic skin contraindications: Acute attacks of gout. Gastric and duodenal reactions, leucopenia, thrombocytopenia, agranulocytosis, aplastic ulcer. Known hypersensitivity to sulfinpyrazone and other pyrazolone anaemia, hepatic dysfunction, jaundice and hepatitis. derivatives. Contra-indicated in patients with asthma, urticaria, or (Please refer to the Summary of Product Characteristics for acute rhinitis, severe parenchymal lesions of the liver or kidneys, detailed information) porphyria, blood dyscrasias, haemorrhagic diatheses overdose: Nausea, vomiting, abdominal pains, diarrhoea, Precautions and warnings: Used with caution in patients with hypotension, cardiac arrhythmias, hyperventilation, respiratory hyperuricaemia or gout, episodes of urolithiasis or renal colic, disorders, impairment of consciousness, coma, epileptic seizures, ensure adequate fluid intake and alkalinisation of the urine during oliguria or anuria, acute renal failure, renal colic.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1 PRODUCT NAME DICLOFENAC SANDOZ 25mg enteric coated tablet 50mg enteric coated tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each Diclofenac Sandoz 25 mg tablet contains Diclofenac Sodium 25mg Each Diclofenac Sandoz 50 mg tablet contains Diclofenac Sodium 50mg Tablets contain lactose. For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM 25 mg Brown-yellow gastro-resistant film coated tablets, round, biconvex faced with a plain rim. Approximate tablet dimensions: diameter 6.1 to 6.3 mm; thickness 2.9 to 3.2 mm. Each tablet contains Diclofenac Sodium Ph Eur 25 mg. 50 mg Brown-yellow gastro-resistant film coated tablets, round, biconvex faced with a banded rim. Approximate tablet dimensions: diameter 8.0 to 8.3 mm; thickness 3.5 to 3.8 mm. Each tablet contains Diclofenac Sodium Ph Eur 50 mg. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of: • Inflammatory and degenerative forms of rheumatism - rheumatoid arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, osteoarthritis and spondylarthritis, painful syndromes of the vertebral column, non-articular rheumatism; • Acute attacks of gout; • Post-traumatic and post-operative pain, inflammation, and swelling, e.g. following dental or orthopaedic surgery; • Painful and/or inflammatory conditions in gynaecology, e.g. primary dysmenorrhoea or adnexitis; • As an adjuvant in severe painful inflammatory infections of the ear, nose, or throat, e.g. pharyngotonsillitis, otitis. In keeping with general therapeutic principles, the underlying Page 1 of 18 NEW ZEALAND DATA SHEET disease should be treated with basic therapy, as appropriate. Fever alone is not an indication. 4.2 Dose and method of administration Dosage Diclofenac Sandoz should only be prescribed when the benefits are considered to outweigh the potential risks.
    [Show full text]
  • Nonsteroidal Antiinflammatory Drugs and Acute Renal Failure in Elderly Persons
    American Journal of Epidemiology Vol. 151, No. 5 Copyright © 2000 by The Johns Hopkins University School of Hygiene and Public Health Printed In U.S.A. Ail rights reserved Nonsteroidal Antiinflammatory Drugs and Acute Renal Failure in Elderly Persons Marie R. Griffin,1'2 Aida Yared,3 and Wayne A. Ray1 Renal prostaglandin inhibition by nonsteroidal antiinflammatory drugs (NSAIDs) may decrease renal function, Downloaded from https://academic.oup.com/aje/article/151/5/488/117194 by guest on 27 September 2021 especially under conditions of low effective circulating volume. To evaluate the risk of important deterioration of renal function due to this effect, the authors performed a nested case-control study using Tennessee Medicaid enrollees aged £65 years in 1987-1991. Cases were patients who had been hospitalized with community- acquired acute renal failure; they were selected on the basis of medical record review of Medicaid enrollees with selected discharge diagnoses. Information on the timing, duration, and dose of prescription NSAIDs used, demographic factors, and comorbidity was gathered from computerized Medicaid-Medicare data files. Of the 1,799 patients with acute renal failure (4.51 hospitalizations per 1,000 person-years), 18.1% were current users of prescription NSAIDs as compared with 11.3% of 9,899 randomly selected population controls. After control for demographic factors and comorbidity, use of NSAIDs increased the risk of acute renal failure 58% (adjusted odds ratio = 1.58; 95% confidence interval (Cl): 1.34, 1.86). For ibuprofen, which accounted for 35% of NSAID use, odds ratios associated with dosages of £1,200 mg/day, >1,200-<2,400 mg/day, and £2,400 mg/day were 0.94 (95% Cl: 0.58, 1.51), 1.89 (95% Cl: 1.34, 2.67), and 2.32 (95% Cl: 1.45, 3.71), respectively (test for linear trend: p = 0.009).
    [Show full text]
  • WO 2010/099522 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date 2 September 2010 (02.09.2010) WO 2010/099522 Al (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 45/06 (2006.01) A61K 31/4164 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/4045 (2006.01) A61K 31/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US2010/025725 HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, (22) International Filing Date: KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, 1 March 2010 (01 .03.2010) ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/156,129 27 February 2009 (27.02.2009) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, HELSINN THERAPEUTICS (U.S.), INC.
    [Show full text]
  • S Salsalate Tablets
    SALSALATE TABLETS CARDIOVASCULAR EFFECTS renal disease. If SALSALATE TABLETS therapy must be initiated, Rx Only Cardiovascular Thrombotic Events close monitoring of the patient’s renal function is advisable. Cardiovascular Risk Clinical trials of several COX-2 selective and nonselective NSAIDs Anaphylactoid Reactions • NSAIDs may cause an increased risk of serious cardiovascular of up to three years duration have shown an increased risk of As with other NSAIDs, anaphylactoid reactions may occur in thrombotic events, myocardial infarction, and stroke, which can serious cardiovascular (CV) thrombotic events, myocardial patients without known prior exposure to SALSALATE TABLETS. be fatal. This risk may increase with duration of use. Patients infarction, and stroke, which can be fatal. All NSAIDs, both COX-2 SALSALATE TABLETS should not be given to patients with the with cardiovascular disease or risk factors for cardiovascular selective and nonselective, may have a similar risk. Patients with aspirin triad. This symptom complex typically occurs in asthmatic disease may be at greater risk. (See WARNINGS and CLINICAL known CV disease or risk factors for CV disease may be at greater patients who experience rhinitis with or without nasal polyps, or TRIALS). risk. To minimize the potential risk for an adverse CV event in who exhibit severe, potentially fatal bronchospasm after taking • SALSALATE TABLETS is contraindicated for the treatment of patients treated with an NSAID, the lowest effective dose should be aspirin or other NSAIDs (see CONTRAINDICATIONS and perioperative pain in the setting of coronary artery bypass graft used for the shortest duration possible. Physicians and patients PRECAUTIONS - Preexisting Asthma). Emergency help should be (CABG) surgery (see WARNINGS Gastrointestinal Risk) should remain alert for the development of such events, even in sought in cases where an anaphylactoid reaction occurs.
    [Show full text]
  • Highlights of Prescribing Information
    HIGHLIGHTS OF PRESCRIBING INFORMATION -----------------------------CONTRAINDICATIONS-------------------------------------­ These highlights do not include all the information needed to use Patients with known hypersensitivity to natural or recombinant hirudins, IPRIVASK safely and effectively. See full prescribing information for and in patients with active bleeding and/or irreversible coagulation IPRIVASK. disorders (4). IPRIVASK® 15 mg (desirudin for injection), for subcutaneous injection -----------------------WARNINGS AND PRECAUTIONS-----------------------------­ Initial U.S. approval: 2003 • Hemorrhage: Bleeding can occur at any site during therapy with WARNING: SPINAL/EPIDURAL HEMATOMAS Iprivask. An unexplained fall in hematocrit or blood pressure should See Full Prescribing Information for complete boxed warning. lead to a search for a bleeding site. Avoid intramuscular injection as When neuraxial anesthesia (epidural/spinal anesthesia) or local bleeding and hematoma formation may result. (5.3). spinal puncture is employed, patients anticoagulated or • Increased Risk of bleeding with Renal Impairment: Dose reductions scheduled to be anticoagulated with selective inhibitors of by factors of three and nine are recommended for patients with thrombin such as Iprivask may be at risk of developing an moderate and severe renal impairment respectively (2.2). In addition, epidural or spinal hematoma which can result in long-term or daily aPTT and serum creatinine monitoring are recommended for permanent paralysis (5.1). patients with moderate
    [Show full text]
  • Chemmart Meloxicam
    Chemmart Meloxicam Capsules Meloxicam Consumer Medicine Information For a copy of a large print leaflet, Ph: 1800 195 055 What is in this leaflet Ask your doctor if you have any swelling of the feet or lips due to questions about why this medicine fluid build-up Read this leaflet carefully before has been prescribed for you. · You experience bleeding from the taking your medicine. Your doctor may have prescribed this stomach, gut or any other This leaflet answers some common medicine for another reason. bleeding questions about meloxicam. It does This medicine is available only with · You have had a stroke resulting not contain all the available a doctor©s prescription. from a bleed in the brain or have information. It does not take the a bleeding disorder place of talking to your doctor or How it works · You currently have a peptic pharmacist. Meloxicam belongs to a family of (stomach) ulcer All medicines have risks and medicines called Non-Steroidal Anti- · You are lactose intolerant (this benefits. Your doctor has weighed inflammatory Drugs (NSAIDs). medicine contains lactose) the risks of you using this medicine These medicines work by relieving · You have Crohn©s Disease or against the benefits they expect it pain and inflammation. Ulcerative Colitis will have for you. There is no evidence that this · You have severe liver or kidney Keep this leaflet with your medicine is addictive. problems medicine. · You are currently taking other You may want to read it again. medicines known as: sulfinpyrazone (used to treat Before you take this gout), fluconazole (used to treat medicine fungal infections) or certain What this medicine is sulfur antibiotics (e.g.
    [Show full text]
  • Information for the User Diclofenac / Omeprazole Modified-Release
    Package Leaflet: Information for the User Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg diclofenac sodium/omeprazole Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. Keep this leaflet. You may need to read it again. If you have any further questions, please ask your doctor or pharmacist. This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg is and what it is used for 2. What you need to know before you take Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 3. How to take Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 4. Possible side effects 5. How to store Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg 6. Contents of the pack and other information 1. What Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg is and what it is used for Diclofenac / Omeprazole modified-release capsules, hard, 75 mg / 20 mg contains two active ingredients in a single capsule. These active ingredients are diclofenac sodium (75 mg) and omeprazole (20 mg). Diclofenac is one of a group of medicines called non-steroidal anti-inflammatory drugs (NSAIDs) and is used to reduce pain and inflammation of joint disorders.
    [Show full text]
  • Gastro-Duodenal Ulcers Associated with the Use of Non-Steroidal Anti-Inflammatory Drugs: a Systematic Review of Preventive Pharmacological Interventions
    Gastro-duodenal Ulcers Associated with the Use of Technology Non-steroidal Anti- inflammatory Drugs: A Systematic Review Report of Preventive Issue 38 September 2003 Pharmacological Interventions Publications can be requested from: CCOHTA 600-865 Carling Avenue Ottawa, Ontario, Canada K1S 5S8 Tel. (613) 226-2553 Fax. (613) 226-5392 Email: [email protected] or download from CCOHTA’s web site: http://www.ccohta.ca Cite as: Rostom A, Dubé C, Jolicoeur E, Boucher M, Joyce J. Gastro-duodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventive pharmacological interventions. Ottawa: Canadian Coordinating Office for Health Technology Assessment; 2003. Technology report no 38. Reproduction of this document for non-commercial purposes is permitted provided appropriate credit is given to CCOHTA. CCOHTA is a non-profit organization funded by the federal, provincial and territorial governments. Legal Deposit - 2003 National Library of Canada ISBN: 1-894620-92-5 (print) ISBN: 1-894620-93-3 (electronic version) Publications Mail Agreement Number: 40026386 Canadian Coordinating Office for Health Technology Assessment Gastro-duodenal Ulcers Associated with the Use of Non-steroidal Anti-inflammatory Drugs: A Systematic Review of Preventive Pharmacological Interventions Alaa Rostom MD MSc FRCPC1 1 Catherine Dubé MD MSc FRCPC 1 Emilie Jolicoeur MD 2 Michel Boucher BPharm MSc 2 Janet Joyce MLS September 2003 ________________________ 1 University of Ottawa, Ottawa, Ontario 2 Canadian Coordinating Office for Health Technology Assessment, Ottawa, Ontario Reviewers These individuals kindly provided comments on this report. External Reviewers Isabelle Chabot, PhD Betsy Miller, BScPharm MSc Manager, Health Economics and Executive Director Outcomes Research Patient Access and Outcomes Research Merck Frosst Canada & Co.
    [Show full text]
  • New Zealand Data Sheet IBUPROFEN LIQUID CAPSULES
    New Zealand Data Sheet IBUPROFEN LIQUID CAPSULES Neo Health Ibuprofen liquid capsules 400mg 1 PRODUCT NAME Ibuprofen 400mg Liquid capsules 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains Ibuprofen 400 mg. For full list of excipients, see section 6.1 3.PHARMACEUTICAL FORM Capsule, soft Natural transparent, oval shaped, soft gelatin capsule containing clear colourless liquid. imprinted with L 160 in Black edible ink. 4.CLINICAL PARTICULARS 4.1 Therapeutic indications This medical product is indicated in adults and children & adolescents 12 years of age and over for the symptomatic treatment of mild to moderate pain and/or inflammation associated with headache, migraine, tension headache, muscular pain, dental pain, period pain, sinus pain, back pain, arthritis pain, cold and flu symptoms. 4.2 Dosage and administration For oral use and short-term use only. Capsules should not be chewed. Undesirable effects may be minimized by using the lowest effective dose for the shortest possible duration necessary to control symptoms (see section 4.4) Adults and children & adolescents 12 years of age and over. Initial dose, one capsule with water. Then, if necessary, one capsule every six hours. Do not exceed six capsules (2400 mg) in any 24-hour period. If in children and adolescents between 12 and 18 years this medicinal product is required for 3 days, or if symptoms worsen a doctor should be consulted. If in adults the product is required for more than 3 days in the case of fever and 4 days for treatment of pain, or if the symptoms worsen the patient is advised to consult a doctor.
    [Show full text]
  • Vinblastine and Sulfinpyrazone Export by the Multidrug Resistance Protein MRP2 Is Associated with Glutathione Export
    British Journal of Cancer (2000) 83(3), 375–383 © 2000 Cancer Research Campaign doi: 10.1054/ bjoc.2000.1262, available online at http://www.idealibrary.com on Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export R Evers1,4, M de Haas1, R Sparidans2, J Beijnen2, PR Wielinga3, J Lankelma3 and P Borst1 1Division of Molecular Biology and Center of Biomedical Genetics, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands; 2Department of Pharmacy, Slotervaart Hospital, Louwesweg 6, 1066 EC Amsterdam, The Netherlands; 3Academic Hospital Vrije Universiteit, Department of Medical Oncology, Room BR232, PO Box 7057, 1007 MB Amsterdam, The Netherlands; 4Present address Georg-Speyer-Haus, Paul Ehrlich straße 42–44, 60596 Frankfurt am, Germany Summary The multidrug resistance proteins MRP1 and MRP2 are members of the same subfamily of ATP-binding cassette transporters. Besides organic molecules conjugated to negatively charged ligands, these proteins also transport cytotoxic drugs for which no negatively charged conjugates are known to exist. In polarized MDCKII cells, MRP1 routes to the lateral plasma membrane, and MRP2 to the apical plasma membrane. In these cells MRP1 transports daunorubicin, and MRP2 vinblastine; both transporters export reduced glutathione (GSH) into the medium. We demonstrate that glutathione transport in MDCKII-MRP1 cells is inhibited by the inhibitors of organic anion transporters sulfinpyrazone, indomethacin, probenecid and benzbromarone. In MDCKII-MRP2 cells, GSH export is stimulated by low concentrations of sulfinpyrazone or indomethacin, whereas export is inhibited down to control levels at high concentrations. We find that unmodified sulfinpyrazone is a substrate for MRP2, also at concentrations where GSH export is inhibited.
    [Show full text]
  • Ibuprofen 600 Mg Film- Coated Tablets
    Package leaflet: Information for the user You should discuss your treatment with your doctor or pharmacist before taking Ibuprofen if Ibuprofen 600 mg film- you: • have heart problems including heart failure, coated tablets angina (chest pain), or if you have had a heart attack, bypass surgery, peripheral Read all of this leaflet carefully before artery disease (poor circulation in the legs you start taking this medicine because it or feet due to narrow or blocked arteries), or contains important information for you. any kind of stroke (including ‘mini-stroke’ or - Keep this leaflet. You may need to read it transient ischaemic attack “TIA”). again. • have high blood pressure, diabetes, high - If you have any further questions, ask your cholesterol, or have a family history of heart doctor or pharmacist. disease or stroke, or if you are a smoker. - This medicine has been prescribed for you Effects on the kidneys only. Do not pass it on to others. It may Ibuprofen may cause problems with kidney harm them, even if their signs of illness are function even in patients who have not had the same as yours. kidney problems before. This may result in - If you get any side effects, talk to your swelling of the legs and may even lead to heart doctor or pharmacist. This includes any failure or high blood pressure in predisposed possible side effects not listed in this leaflet. individuals. See section 4. Ibuprofen may cause kidney damage especially What is in this leaflet in patients who already have kidney, heart or 1. What Ibuprofen is and what it is used for liver problems, or are taking diuretics or ACE 2.
    [Show full text]